Skip to main content
. 2019 Mar 5;9:3525. doi: 10.1038/s41598-019-40203-7

Figure 2.

Figure 2

Evolution of anti-BP180 (panel A) and anti-BP230 (panel B) antibody ELISA values in sera from BP patients after Rituximab therapy. Blue lines correspond to patients who achieved complete remission off therapy (CRoffT). Red lines correspond to patients who were in complete remission on minimal therapy (CRMT).